MedTrace Logo

PRION-1: Quinacrine for Human Prion Disease

NCT00104663 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-04-07

No results posted yet for this study

Summary

PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion disease that can be refined or expanded in the future, as new agents become available.

Conditions

  • Prion Disease

Interventions

DRUG

Quinacrine

Sponsors & Collaborators

Principal Investigators

  • John Collinge, MD, FRCP · MRC Prion Unit

  • Janet Darbyshire, MBChB, FRCP · MRC Clinical Trials Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2007-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00104663 on ClinicalTrials.gov